A Phase 1 interventional study of Pimasertib and Pimasertib in Advanced Solid Tumor, sponsored by EMD Serono. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-30.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The research trial is testing the experimental drug pimasertib and the drug Torisel, given together, in the treatment of advanced solid tumors. The primary purpose of the study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of the drug combination.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 33 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria also apply.
Exclusion Criteria:
Additional exclusion criteria also apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pimasertib · Drug: Temsirolimus
Drug: Pimasertib · Drug: Temsirolimus
Drug: Pimasertib · Drug: Temsirolimus
Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Also known as: MSC1936369B
Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Also known as: MSC1936369B
Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Number of Subjects With Dose Limiting Toxicities (DLTs)
DLT was defined as any of the following toxicities graded as per National Cancer Institute (NCI) common terminology criteria for adverse events (NCI CTCAE v4.0) encountered within cycle 1 of treatment at any dose level and judged not to be related to the underlying disease or concomitant medications. A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation would expose subjects to unacceptable risk; any Grade \>=3 non-hematological toxicity except Grade 3 asymptomatic increases in liver function tests, diarrhea, nausea or vomiting with duration \<= 48 hours and alopecia; Grade 4 neutropenia of \>5 days duration or febrile neutropenia of \>1 day duration; Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; any treatment interruption \>2 weeks due to adverse events; any severe, impairing daily functions or life-threatening, complication or abnormality not defined in NCI-CTCAE that is attributable to the therapy.
Time frame: Up to 21 Days (within Cycle 1)
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. The TEAEs were those events that occur between first dose of trial treatment and up to 30 days after last dose of the trial treatment that were absent before treatment or that worsened relative to pretreatment state.
Time frame: From the start of the trial treatment until data cut-off date (23 February 2012)
Maximum Plasma Concentration (Cmax) of Pimasertib
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: Drug-drug interaction (DDI) cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Maximum Plasma Concentration (Cmax) of Temsirolimus
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 8
Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Time to Reach Maximum Plasma Concentration (Tmax) of Temsirolimus
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) and Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib
The AUCtau was defined as the area under the concentration curve divided by the dosing interval. AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1 for AUCtau; DDI cohorts: Day 1 of Cycle 1 AUC0-inf
Area Under Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Temsirolimus
The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Apparent Terminal Half-life (t1/2) of Pimasertib
The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Apparent Terminal Half-life (t1/2) of Temsirolimus
The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Apparent Clearance From Plasma Following Oral Administration (CL/f) of Pimasertib
Clearance (CL) of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. The CL obtained after oral dose (CL/F) was influenced by the fraction of the dose absorbed (bioavailability). Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Total Body Clearance From Plasma Following Intravenous Administration (CL) of Temsirolimus
The clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Apparent Volume of Distribution (Vz/F) of Pimasertib
Volume of distribution (Vz) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz after oral dose (Vz/F) was influenced by the fraction absorbed. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Volume of Distribution (Vz) of Temsirolimus
The Vz was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Number of Subjects With Disease Control Rate
Disease control is defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) \>=12 weeks), based on tumor assessments as determined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0. CR: The disappearance of all lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline. SD: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since treatment started.
Time frame: From the start of the trial treatment until data cut-off date (23 February 2012)
Phospho Extracellular Signal Regulated Kinase (pERK ) Levels and Phospho Ribosomal Protein S6 (pS6) Levels in in Peripheral Blood Mononuclear Cells (PBMCs)
During the first cycle (either Cycle 1 non-DDI or Cycle 1-DDI) blood samples will be collected for pharmacodynamic marker assessments by flow cytometry such as phospho-ERK and phospho- S6 activities in PBMCs
Time frame: DDI cohorts: Days 1, 9 and 10 of Cycle 1; Non-DDI cohorts: Days 1, 8 and 9 of Cycle 1
First/last subject (informed consent): 27 May 2011/23 August 2012. Last subject completed: 23 February 2012; Subjects randomized at 2 centers in United States.
| Milestone | Pimasertib 45 mg+Temsirolimus 12.5 mg | Pimasertib 45 mg+Temsirolimus 25 mg | Pimasertib 75 mg+Temsirolimus 25 mg |
|---|---|---|---|
| Started | 4 | 23 | 6 |
| Completed | 4 | 23 | 6 |
| Not completed | 0 | 0 | 0 |
DLT was defined as any of the following toxicities graded as per National Cancer Institute (NCI) common terminology criteria for adverse events (NCI CTCAE v4.0) encountered within cycle 1 of treatment at any dose level and judged not to be related to the underlying disease or concomitant medications. A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation would expose subjects to unacceptable risk; any Grade \>=3 non-hematological toxicity except Grade 3 asymptomatic increases in liver function tests, diarrhea, nausea or vomiting with duration \<= 48 hours and alopecia; Grade 4 neutropenia of \>5 days duration or febrile neutropenia of \>1 day duration; Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; any treatment interruption \>2 weeks due to adverse events; any severe, impairing daily functions or life-threatening, complication or abnormality not defined in NCI-CTCAE that is attributable to the therapy.
| subjects | Pimasertib 45 mg+Temsirolimus 12.5 mg | Pimasertib 45 mg+Temsirolimus 25 mg | Pimasertib 75 mg+Temsirolimus 25 mg |
|---|---|---|---|
| Number of Subjects With Dose Limiting Toxicities (DLTs) | 0 | 7 | 2 |
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. The TEAEs were those events that occur between first dose of trial treatment and up to 30 days after last dose of the trial treatment that were absent before treatment or that worsened relative to pretreatment state.
| subjects | Pimasertib 45 mg+Temsirolimus 12.5 mg | Pimasertib 45 mg+Temsirolimus 25 mg | Pimasertib 75 mg+Temsirolimus 25 mg |
|---|---|---|---|
| Number of Subjects With Treatment-emergent Adverse Events (TEAEs) | 4 | 23 | 6 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| nanogram/milliliter | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 1 | 185.2 (87.38 to 266.5) | 193.5 (97.24 to 326.5) | — | — |
| DDI: Day 9 | 131 (68.75 to 190.5) | 192.1 (63.8 to 406) | — | — |
| Non-DDI: Day 8 | — | — | 197.6 (73.75 to 317.3) | 308.1 (157.3 to 460) |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| nanogram/milliliter | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 9 | 457.5 (361.6 to 578.1) | 505.3 (396.8 to 591.4) | — | — |
| DDI: Day 16 | 281.1 (13.21 to 636.4) | 511.8 (184.6 to 575.9) | — | — |
| Non-DDI: Day 8 | — | — | 489.9 (391.9 to 525.5) | 480.9 (323.3 to 589.7) |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| hour | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 1 | 1 (0.5333 to 2) | 1.5 (0 to 4) | — | — |
| DDI: Day 9 | 2.3 (0.9167 to 4.033) | 1.133 (0.5 to 2.667) | — | — |
| Non-DDI: Day 8 | — | — | 1.5 (1 to 3.967) | 0.5833 (0.5 to 3) |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| hour | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 9 | 0.7417 (0.5167 to 1) | 0.5667 (0.5 to 1.017) | — | — |
| DDI: Day 16 | 0.9333 (0.5 to 24.05) | 0.5 (0.5 to 1.55) | — | — |
| Non-DDI: Day 8 | — | — | 0.5 (0.5 to 0.55) | 0.55 (0.4333 to 0.5833) |
The AUCtau was defined as the area under the concentration curve divided by the dosing interval. AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| hour*nanogram/milliliter | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: AUCtau: Day 9 | 628 (435.6 to 1338) | 805 (264.3 to 1623) | — | — |
| Non-DDI: AUCtau: Day 8 | — | — | 706 (333.8 to 2548) | 1402 (922.2 to 1735) |
| DDI: AUC0-inf: Day 1 | 573.2 (393.5 to 1703) | 828.6 (373.3 to 1310) | — | — |
The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| hour*nanogram/milliliter | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 9 | 2452 (1670 to 4440) | 2130 (1534 to 3642) | — | — |
| DDI: Day 16 | 2006 (1174 to 2837) | 2743 (1977 to 3219) | — | — |
| Non-DDI: Day 8 | — | — | 4026 (2386 to 4783) | 2194 (1324 to 2483) |
The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| hour | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 1 | 5.915 (4.718 to 6.652) | 5.886 (2.504 to 20.25) | — | — |
| DDI: Day 9 | 6.08 (2.101 to 11.17) | 5.896 (2.013 to 23.86) | — | — |
| Non-DDI: Day 8 | — | — | 7.746 (5.625 to 9.993) | 5.712 (2.365 to 8.656) |
The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| hour | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 9 | 25.57 (10.39 to 54.46) | 13.2 (9.237 to 34.92) | — | — |
| DDI: Day 16 | 20.62 (12.97 to 28.27) | 19.14 (13.54 to 25.82) | — | — |
| Non-DDI: Day 8 | — | — | 29.08 (26.14 to 44.14) | 10.42 (9.192 to 13.76) |
Clearance (CL) of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. The CL obtained after oral dose (CL/F) was influenced by the fraction of the dose absorbed (bioavailability). Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| liter/hour | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 1 | 81.25 (26.42 to 114.4) | 54.36 (34.36 to 120.6) | — | — |
| DDI: Day 9 | 71.99 (33.63 to 103.3) | 55.9 (27.73 to 170.3) | — | — |
| Non-DDI: Day 8 | — | — | 64.31 (17.66 to 134.8) | 53.6 (43.22 to 81.33) |
The clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| liter/hour | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 9 | 5.378 (2.815 to 7.486) | 11.73 (6.863 to 16.29) | — | — |
| DDI: Day 16 | 7.528 (4.406 to 10.65) | 9.292 (7.766 to 12.64) | — | — |
| Non-DDI: Day 8 | — | — | 6.284 (5.227 to 10.48) | 11.39 (10.07 to 18.89) |
Volume of distribution (Vz) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz after oral dose (Vz/F) was influenced by the fraction absorbed. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| liter | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus (TEM) 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 1 | 691.3 (210.3 to 923) | 536.5 (199.4 to 1450) | — | — |
| DDI: Day 9 | 517.6 (274.4 to 1080) | 519.5 (157.3 to 1768) | — | — |
| Non-DDI: Day 8 | — | — | 760.6 (143.3 to 1840) | 416.5 (190.4 to 745.5) |
The Vz was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.
| liter | Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) |
|---|---|---|---|---|
| DDI: Day 9 | 152 (99.01 to 326.1) | 244.5 (142.2 to 505.4) | — | — |
| DDI: Day 16 | 189.5 (179.6 to 199.3) | 233 (216.1 to 394.4) | — | — |
| Non-DDI: Day 8 | — | — | 309.7 (203.6 to 471.3) | 172.9 (133.5 to 375) |
Disease control is defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) \>=12 weeks), based on tumor assessments as determined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0. CR: The disappearance of all lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline. SD: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since treatment started.
No measurements were reported for this outcome.
During the first cycle (either Cycle 1 non-DDI or Cycle 1-DDI) blood samples will be collected for pharmacodynamic marker assessments by flow cytometry such as phospho-ERK and phospho- S6 activities in PBMCs
No measurements were reported for this outcome.
Collected over From the start of the trial treatment until data cut-off date (23 February 2012). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pimasertib 45 mg+Temsirolimus 12.5 mg | — | 3/4 (75%) | 4/4 (100%) |
| Pimasertib 45 mg+Temsirolimus 25 mg | — | 17/23 (73.9%) | 23/23 (100%) |
| Pimasertib 75 mg+Temsirolimus 25 mg | — | 5/6 (83.3%) | 6/6 (100%) |
| Event | Pimasertib 45 mg+Temsirolimus 12.5 mg | Pimasertib 45 mg+Temsirolimus 25 mg | Pimasertib 75 mg+Temsirolimus 25 mg |
|---|---|---|---|
| StomatitisGastrointestinal disorders | 0/4 | 2/23 | 2/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 1/23 | 2/6 |
| NauseaGastrointestinal disorders | 1/4 | 0/23 | 1/6 |
| VomitingGastrointestinal disorders | 1/4 | 0/23 | 1/6 |
| Abdominal pain lowerGastrointestinal disorders | 1/4 | 0/23 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 0/23 | 0/6 |
| Enterocutaneous fistulaGastrointestinal disorders | 1/4 | 0/23 | 0/6 |
| Abdominal wall abscessInfections and infestations | 1/4 | 0/23 | 0/6 |
| FallInjury, poisoning and procedural complications | 1/4 | 0/23 | 0/6 |
| Balance disorderNervous system disorders | 1/4 | 0/23 | 0/6 |
| Event | Pimasertib 45 mg+Temsirolimus 12.5 mg | Pimasertib 45 mg+Temsirolimus 25 mg | Pimasertib 75 mg+Temsirolimus 25 mg |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/4 | 13/23 | 5/6 |
| StomatitisGastrointestinal disorders | 2/4 | 15/23 | 5/6 |
| RashSkin and subcutaneous tissue disorders | 0/4 | 6/23 | 5/6 |
| AnaemiaBlood and lymphatic system disorders | 3/4 | 9/23 | 2/6 |
| Rash macularSkin and subcutaneous tissue disorders | 3/4 | 1/23 | 0/6 |
| FatigueGeneral disorders | 2/4 | 13/23 | 2/6 |
| PyrexiaGeneral disorders | 2/4 | 5/23 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 9/23 | 1/6 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 9/23 | 1/6 |
| HypokalaemiaMetabolism and nutrition disorders | 1/4 | 8/23 | 0/6 |
The safety analysis set included all the subjects who received at least one administration of trial medication.
| Age, Continuous(years) | Pimasertib 45 mg+Temsirolimus 12.5 mg | Pimasertib 45 mg+Temsirolimus 25 mg | Pimasertib 75 mg+Temsirolimus 25 mg | Total |
|---|---|---|---|---|
| Mean | 63.3 ± 11.30 | 57.9 ± 14.09 | 55.5 ± 6.19 | 58.1 ± 12.61 |
| Sex: Female, Male(Participants) | Pimasertib 45 mg+Temsirolimus 12.5 mg | Pimasertib 45 mg+Temsirolimus 25 mg | Pimasertib 75 mg+Temsirolimus 25 mg | Total |
|---|---|---|---|---|
| Female | 2 | 16 | 4 | 22 |
| Male | 2 | 7 | 2 | 11 |
Ran from May 2011 to primary completion in Feb 2012, 8 months.
Results were first posted in Jul 2018, 6 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pimasertib